SHA:688166

2 stories mentioning SHA:688166Updated 43d ago

Every FINWIRES story that references SHA:688166, newest first.

BrightGene Resubmits Hong Kong IPO Application

BrightGene Bio-Medical Technology (SHA:688166) has resubmitted its application to launch an initial public offering on the Hong Kong Stock Exchange.The pharmaceutical company filed a new draft application on Monday, according to a Tuesday filing with the Shanghai bourse.The proposed listing still requires regulatory approvals, including from the China Securities Regulatory Commission and Hong Kong's Securities and Futures Commission.BrightGene plans to use a portion of the proceeds for research and development of its products, including its BGM0504 injection for the treatment of obesity.Huatai International is the sole sponsor of the proposed IPO.

SHA:688166

Asia56d ago

Participants of BrightGene's Phase 3 Trial See Trimmed Waistlines

Participants of BrightGene Bio-Medical Technology's (SHA:688166) phase 3 clinical trial lost weight and reduced their waistlines during the study, according to a Wednesday disclosure to the Shanghai bourse.The company said the BGM0504 weight loss injection met primary and secondary endpoints during the trial.Blood pressure among participants, who were either overweight or obese, also improved, the filing said.

SHA:688166

Track with the FINWIRES app suite

FolioX

Track SHA:688166 in your portfolio

WheelAI

Analyze SHA:688166 options with the wheel strategy

StockInsider

See market sentiment on SHA:688166